DE69435332D1 - Herstellung von menschlichem Papillomaviren Hüllprotein und Virus-ähnlichen Teilchen - Google Patents

Herstellung von menschlichem Papillomaviren Hüllprotein und Virus-ähnlichen Teilchen

Info

Publication number
DE69435332D1
DE69435332D1 DE69435332T DE69435332T DE69435332D1 DE 69435332 D1 DE69435332 D1 DE 69435332D1 DE 69435332 T DE69435332 T DE 69435332T DE 69435332 T DE69435332 T DE 69435332T DE 69435332 D1 DE69435332 D1 DE 69435332D1
Authority
DE
Germany
Prior art keywords
virus
particles
preparation
envelope protein
human papillomavirus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69435332T
Other languages
English (en)
Inventor
Robert C Rose
William Bonnez
Richard C Reichman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Rochester
Original Assignee
University of Rochester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26703787&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69435332(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/028,517 external-priority patent/US8062642B1/en
Application filed by University of Rochester filed Critical University of Rochester
Application granted granted Critical
Publication of DE69435332D1 publication Critical patent/DE69435332D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69435332T 1993-03-09 1994-03-08 Herstellung von menschlichem Papillomaviren Hüllprotein und Virus-ähnlichen Teilchen Expired - Lifetime DE69435332D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/028,517 US8062642B1 (en) 1993-03-09 1993-03-09 Production of papillomavirus capsid protein and virus-like particles
US20730994A 1994-03-07 1994-03-07

Publications (1)

Publication Number Publication Date
DE69435332D1 true DE69435332D1 (de) 2011-02-17

Family

ID=26703787

Family Applications (9)

Application Number Title Priority Date Filing Date
DE69435332T Expired - Lifetime DE69435332D1 (de) 1993-03-09 1994-03-08 Herstellung von menschlichem Papillomaviren Hüllprotein und Virus-ähnlichen Teilchen
DE201112100018 Pending DE122011100018I1 (de) 1993-03-09 1994-03-08 Herstellung von menschlichem Papilloma-Virus-Capsid-Protein und virusahnlichen Teilchen.
DE69435331T Expired - Lifetime DE69435331D1 (de) 1993-03-09 1994-03-08 Herstellung von menschlichen papillomavirus HBV-11 Kapsidprotein L1 und Virus-ähnliche Partikeln
DE05075369T Pending DE05075369T1 (de) 1993-03-09 1994-03-08 Herstellung von menschlichem Papilloma-Virus-Capsid-Protein und virusähnlichen Teilchen
DE69434383T Expired - Lifetime DE69434383T2 (de) 1993-03-09 1994-03-08 Herstellung von menschlichem papillomavirus hüllprotein und virus-ähnlichen teilchen
DE05075889T Pending DE05075889T1 (de) 1993-03-09 1994-03-08 Herstellung von menschlichem Papilloma-Virus HBV-11-Capsid-Protein L1 und virusähnlichen Teilchen
DE122007000089C Pending DE122007000089I1 (de) 1993-03-09 1994-03-08 Herstellung von menschlichem papillomavirus hüllprotein und virus-ähnlichen teilchen
DE1994634383 Pending DE122007000014I1 (de) 1993-03-09 1994-03-08 Herstellung von menschlichem Papillomavirus Hüllprotein und virus-ähnlichen Teilchen
DE122007000090C Pending DE122007000090I1 (de) 1993-03-09 1994-03-08 Herstellung von menschlichem papillomavirus hüllprotein und virus-ähnlichen teilchen

Family Applications After (8)

Application Number Title Priority Date Filing Date
DE201112100018 Pending DE122011100018I1 (de) 1993-03-09 1994-03-08 Herstellung von menschlichem Papilloma-Virus-Capsid-Protein und virusahnlichen Teilchen.
DE69435331T Expired - Lifetime DE69435331D1 (de) 1993-03-09 1994-03-08 Herstellung von menschlichen papillomavirus HBV-11 Kapsidprotein L1 und Virus-ähnliche Partikeln
DE05075369T Pending DE05075369T1 (de) 1993-03-09 1994-03-08 Herstellung von menschlichem Papilloma-Virus-Capsid-Protein und virusähnlichen Teilchen
DE69434383T Expired - Lifetime DE69434383T2 (de) 1993-03-09 1994-03-08 Herstellung von menschlichem papillomavirus hüllprotein und virus-ähnlichen teilchen
DE05075889T Pending DE05075889T1 (de) 1993-03-09 1994-03-08 Herstellung von menschlichem Papilloma-Virus HBV-11-Capsid-Protein L1 und virusähnlichen Teilchen
DE122007000089C Pending DE122007000089I1 (de) 1993-03-09 1994-03-08 Herstellung von menschlichem papillomavirus hüllprotein und virus-ähnlichen teilchen
DE1994634383 Pending DE122007000014I1 (de) 1993-03-09 1994-03-08 Herstellung von menschlichem Papillomavirus Hüllprotein und virus-ähnlichen Teilchen
DE122007000090C Pending DE122007000090I1 (de) 1993-03-09 1994-03-08 Herstellung von menschlichem papillomavirus hüllprotein und virus-ähnlichen teilchen

Country Status (14)

Country Link
EP (3) EP1588713B1 (de)
JP (4) JPH08507685A (de)
AT (3) ATE296111T1 (de)
AU (3) AU688759C (de)
CA (1) CA2157932C (de)
DE (9) DE69435332D1 (de)
DK (2) DK1618888T3 (de)
ES (3) ES2263406T3 (de)
FR (1) FR11C0022I2 (de)
HK (2) HK1082196A1 (de)
LU (3) LU91313I2 (de)
NL (3) NL300265I2 (de)
PT (2) PT1618888E (de)
WO (1) WO1994020137A1 (de)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG48769A1 (en) 1991-07-19 1998-05-18 Univ Queensland Papilloma virus vaccine
US5437951A (en) * 1992-09-03 1995-08-01 The United States Of America As Represented By The Department Of Health And Human Services Self-assembling recombinant papillomavirus capsid proteins
US6153201A (en) * 1993-03-09 2000-11-28 University Of Rochester Oral immunization with papillomavirus virus-like particles
AUPM358894A0 (en) * 1994-01-31 1994-02-24 Csl Limited Modified papilloma virus l2 protein and vlps formed therefrom
DE4415743C2 (de) 1994-05-04 1996-10-10 Deutsches Krebsforsch Papillomviren, Mittel zu deren Nachweis sowie zur Therapie von durch sie verursachten Erkrankungen
US5888516A (en) * 1994-05-16 1999-03-30 Merck & Co. Inc. Recombinant papillomavirus vaccines
AUPM566794A0 (en) * 1994-05-17 1994-06-09 University Of Queensland, The Process and product
WO1996011272A2 (de) 1994-10-07 1996-04-18 Medigene Gesellschaft Für Molekularbiologische Diagnostik, Theraphie Und Technologie Mbh Papillomavirusähnliche partikel, fusionsproteine sowie verfahren zu deren herstellung
AU2003235191B2 (en) * 1994-10-07 2006-09-21 Loyola University Of Chicago Papilloma virus-like particles, fusion proteins as well as processes for their production
AR004464A1 (es) * 1994-11-14 1998-12-16 Merck Sharp & Dohme Un metodo para producir una proteina de capside de papilomavirus
JP3958360B2 (ja) * 1995-02-24 2007-08-15 キャンタブ ファーマシューティカルズ リサーチ リミティド 免疫治療剤として役立つポリペプチド及びポリペプチド調製の方法
IL117459A (en) * 1995-03-22 2005-11-20 Merck & Co Inc Dna encoding human papillomavirus type 18
US5820870A (en) * 1995-03-22 1998-10-13 Merck & Co., Inc. Recombinant human papillomavirus type 18 vaccine
US5840306A (en) * 1995-03-22 1998-11-24 Merck & Co., Inc. DNA encoding human papillomavirus type 18
US5821087A (en) * 1995-03-30 1998-10-13 Merck & Co., Inc. Production of recombinant human papillomavirus type II protein utilizing papillomavirus 6/11 hybrid DNA
IL117591A0 (en) * 1995-03-30 1996-07-23 Merck & Co Inc Synthetic DNA encoding human papillomavirus type 11 L1 protein
DE69631380T2 (de) * 1995-11-15 2004-11-04 Merck & Co., Inc. Synthetische hpv11 virusartige partikel
DE19543553B4 (de) * 1995-11-22 2009-04-09 Deutsches Primatenzentrum Gmbh VP-Antigene des JC-Virus
US6908615B1 (en) 1996-03-18 2005-06-21 Merck & Co., Inc. DNA encoding human papilloma virus type 18
FR2749323B1 (fr) * 1996-06-04 1998-07-10 Pasteur Merieux Serums Vacc Pseudo-particules virales utiles en tant que vecteur de delivrance d'acide nucleique
WO1998014564A1 (en) * 1996-10-04 1998-04-09 Merck & Co., Inc. Synthetic hpv16 virus-like particles
EP0948351B1 (de) * 1996-12-09 2004-02-25 Merck & Co., Inc. Synthetische hpv-16 virusähnliche partikel
US6228368B1 (en) * 1997-10-06 2001-05-08 Loyola University Of Chicago Papilloma virus capsomere formulations and method of use
CA2229955C (en) 1998-02-20 2003-12-09 Medigene Gmbh Papilloma virus capsomere vaccine formulations and methods of use
US7494658B2 (en) 1998-02-20 2009-02-24 Medigene Ag Papilloma virus truncated L1 protein and fusion protein constructs
US20020039584A1 (en) 1998-02-20 2002-04-04 Medigene Ag Papilloma virus capsomere vaccine formulations and methods of use
US7182947B2 (en) 1998-02-20 2007-02-27 Medigene Ag Papillomavirus truncated L1 protein and fusion protein constructs
US6926897B1 (en) 1998-03-24 2005-08-09 Medigene Aktiengesellschaft Medicament for the avoidance or treatment of papillomavirus-specific tumour
US6692752B1 (en) 1999-09-08 2004-02-17 Smithkline Beecham Biologicals S.A. Methods of treating human females susceptible to HSV infection
DE19925199A1 (de) 1999-06-01 2000-12-07 Medigene Ag Zytotoxische T-Zellepitope des Papillomavirus L1-Proteins und ihre Verwendung in Diagnostik und Therapie
DE19925235A1 (de) 1999-06-01 2000-12-07 Medigene Ag Zytotoxische T-Zellepitope des Papillomavirus L1-Proteins und ihre Verwendung in Diagnostik und Therapie
WO2002024961A1 (en) * 2000-09-18 2002-03-28 Medimmune, Inc. In vitro assay for measuring the immunogenicity of a vaccine
GB0109297D0 (en) 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Vaccine
DE60236806D1 (de) 2001-08-13 2010-08-05 Univ Rochester Transkutane immunisierung gegen papillomavirus mit virusähnlichen papillomaviruspartikeln
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
ES2359473T3 (es) 2003-07-21 2011-05-23 Transgene S.A. Citoquinas multifuncionales.
US7691579B2 (en) 2005-04-15 2010-04-06 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Methods and compositions for producing an enhanced immune response to a human papillomavirus immunogen
WO2006065166A1 (fr) * 2005-07-26 2006-06-22 Obschestvo S Ogranichennoi Otvetstvennostyu 'rusgen' Composition de traitement et de prevention de l'infection de l'humain par le papillomavirus sur la base de la proteine l1 et des peptides de la proteine e7
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
WO2008082719A2 (en) 2006-08-30 2008-07-10 University Of Rochester Combined human papillomavirus vlp/gene delivery system and use thereof as a vaccine for prophylaxis and immunotherapy of infectious diseases and tumors
SI2068918T1 (sl) 2006-09-26 2012-09-28 Infectious Disease Res Inst Si - ep sestavek za cepljenje, ki vsebuje sintetiäśna pomagala
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
PL2137210T3 (pl) 2007-03-02 2017-06-30 Glaxosmithkline Biologicals Sa Nowy sposób i kompozycje
US9428555B2 (en) 2007-04-29 2016-08-30 Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. Truncated L1 protein of Human Papillomavirus type 16
US9364529B2 (en) 2007-04-29 2016-06-14 Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. Truncated L1 protein of human papillomavirus type 18
EP2154149B1 (de) * 2007-05-29 2019-07-10 Xiamen University Verkürztes l1-protein des humanen papillomavirus 6
DK2154148T3 (en) 2007-05-29 2016-09-19 Univ Xiamen Truncated L1 protein of human papillomavirus 11
WO2009092113A2 (en) * 2008-01-19 2009-07-23 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for the delivery of vaccines to disrupted epithelium
CN106377767A (zh) 2008-05-26 2017-02-08 卡迪拉保健有限公司 麻疹‑人乳头瘤组合疫苗
GB0815872D0 (en) 2008-09-01 2008-10-08 Pasteur Institut Novel method and compositions
GB0820822D0 (en) 2008-11-13 2008-12-24 Inst Catala D Oncologia Novel product and processes
WO2010112533A1 (en) * 2009-04-03 2010-10-07 Deutsches Krebsforschungszentrum Enhanced production of papillomavirus-like particles with a modified baculovirus expression system
RU2732574C2 (ru) 2009-06-05 2020-09-21 Инфекшес Дизиз Рисерч Инститьют Синтетические глюкопиранозиллипидные адъюванты
WO2011026111A1 (en) 2009-08-31 2011-03-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Oral delivery of a vaccine to the large intestine to induce mucosal immunity
EP2556377B1 (de) 2010-04-08 2017-07-12 University of Pittsburgh - Of the Commonwealth System of Higher Education Zellenassay mit b-zellen-antigenen
CA2832307A1 (en) 2011-04-08 2012-10-18 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
CN110339160A (zh) 2012-02-07 2019-10-18 传染性疾病研究院 包含tlr4激动剂的改进佐剂制剂及其使用方法
US20150110824A1 (en) 2012-03-18 2015-04-23 Glaxosmithkline Biologicals, Sa Method of vaccination against human papillomavirus
NZ701881A (en) 2012-05-16 2016-10-28 Immune Design Corp Vaccines for hsv-2
CN109134640A (zh) 2012-10-23 2019-01-04 爱默蕾大学 Gm-csf和il-4轭合物、组合物以及与其相关的方法
AU2014253791B2 (en) 2013-04-18 2019-05-02 Immune Design Corp. GLA monotherapy for use in cancer treatment
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
EA201691348A1 (ru) 2013-12-31 2016-11-30 Инфекшес Дизиз Рисерч Инститьют Однофлаконные вакцинные составы
JP7005504B2 (ja) 2016-02-22 2022-01-21 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー 生体分子の固定化方法
MX2018013640A (es) 2016-05-16 2019-08-01 Infectious Disease Res Inst Liposomas pegiladas y metodos de uso.
ES2929054T3 (es) 2016-05-16 2022-11-24 Access To Advanced Health Inst Formulación que contiene un agonista de TLR y métodos de uso
KR20220165789A (ko) 2016-06-01 2022-12-15 액세스 투 어드밴스드 헬스 인스티튜트 사이징제를 함유하는 나노명반 입자
MX2019015076A (es) 2017-06-15 2020-08-03 Infectious Disease Res Inst Portadores lípidos nanoestructurados y emulsiones estables y usos de los mismos.
AU2018330165A1 (en) 2017-09-08 2020-04-02 Access To Advanced Health Institute Liposomal formulations comprising saponin and methods of use
EP3976092A1 (de) 2019-05-25 2022-04-06 Infectious Disease Research Institute Zusammensetzung und verfahren zum sprühtrocknen einer adjuvans-impfstoff-emulsion
US20230310323A1 (en) 2020-09-04 2023-10-05 Access To Advanced Health Institute Co-lyophilized rna and nanostructured lipid carrier
JP2024506364A (ja) 2021-02-11 2024-02-13 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Ｈｐｖワクチンの製造
WO2024052882A1 (en) 2022-09-09 2024-03-14 Access To Advanced Health Institute Immunogenic vaccine composition incorporating a saponin
CN116375816B (zh) * 2023-01-06 2023-09-05 北京康乐卫士生物技术股份有限公司 一种人乳头瘤病毒56型l1蛋白突变体及减少重组蛋白降解的方法及应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4956288A (en) * 1988-04-22 1990-09-11 Biogen, Inc. Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA
NZ232913A (en) * 1989-03-15 1992-08-26 Gist Brocades Nv Il-3 produced recombinantly and purified to homogeneity; vectors and pharmaceutical preparations
SG48769A1 (en) * 1991-07-19 1998-05-18 Univ Queensland Papilloma virus vaccine

Also Published As

Publication number Publication date
WO1994020137A1 (en) 1994-09-15
JP2007075117A (ja) 2007-03-29
EP1588713A1 (de) 2005-10-26
DE122011100018I1 (de) 2011-11-17
DE122007000089I1 (de) 2008-03-27
AU2007201006A1 (en) 2007-03-29
ES2263405T3 (es) 2011-04-20
DE122007000090I1 (de) 2008-03-27
NL300309I1 (nl) 2008-02-01
LU91313I2 (fr) 2007-04-23
AU2007201005A1 (en) 2007-03-29
NL300310I1 (nl) 2008-02-01
NL300265I1 (nl) 2007-05-01
AU2007201006B2 (en) 2010-07-01
JP2010148514A (ja) 2010-07-08
LU91392I2 (fr) 2008-02-14
LU91391I2 (fr) 2008-02-14
DE05075889T1 (de) 2006-10-05
NL300309I2 (nl) 2008-03-03
NL300265I2 (nl) 2008-05-01
FR11C0022I2 (fr) 2012-08-03
AU2007201005B2 (en) 2010-06-10
AU688759C (en) 2006-12-21
ES2242955T4 (es) 2010-04-12
HK1082206A1 (en) 2006-06-02
EP1588713B1 (de) 2010-12-22
HK1082196A1 (en) 2006-06-02
EP0688227A4 (de) 1996-05-29
ES2242955T3 (es) 2005-11-16
DK1618888T3 (da) 2011-04-04
EP0688227B1 (de) 2005-05-25
EP1618888B1 (de) 2011-01-05
DE69435331D1 (de) 2011-02-03
DE69434383D1 (de) 2005-06-30
DK0688227T3 (da) 2005-06-27
ES2263405T1 (es) 2006-12-16
ES2263406T1 (es) 2006-12-16
JP5386392B2 (ja) 2014-01-15
AU688759B2 (en) 1998-03-19
DE69434383T2 (de) 2005-11-24
JP2010099091A (ja) 2010-05-06
EP1618888A1 (de) 2006-01-25
JPH08507685A (ja) 1996-08-20
PT1618888E (pt) 2011-04-08
ATE494005T1 (de) 2011-01-15
AU6443694A (en) 1994-09-26
ATE492289T1 (de) 2011-01-15
CA2157932C (en) 2011-10-11
FR11C0022I1 (de) 2011-05-08
JP4486075B2 (ja) 2010-06-23
EP0688227A1 (de) 1995-12-27
ATE296111T1 (de) 2005-06-15
JP5306251B2 (ja) 2013-10-02
DE05075369T1 (de) 2006-11-16
CA2157932A1 (en) 1994-09-15
ES2263406T3 (es) 2011-06-06
PT688227E (pt) 2005-10-31
DE122007000014I1 (de) 2007-05-24

Similar Documents

Publication Publication Date Title
DE69435332D1 (de) Herstellung von menschlichem Papillomaviren Hüllprotein und Virus-ähnlichen Teilchen
DK0809700T3 (da) Papillomaviruslignende partikler, fusionsproteiner samt fremgangsmåde til fremstilling heraf
DE69535018D1 (de) Papillomavirus vakzine
ATE288489T1 (de) Vp-antigene des jc-virus
EP0868522A4 (de) Rekombinantes pockenvirus der infektiösen peritonitis der katze, zusammensetzungen dessen und methoden zur herstellung und verwendung
DK0750669T3 (da) Modificeret papillomavirus-L2-protein og VLP'er dannet derudfra
ATE290093T1 (de) EXPRIMIERUNG EINES MODIFIZIERTEM ßFOAMY VIRUS ENVELOPE PROTEINß (HÜLLENPROTEIN)